Background-Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for thrombin on human platelets, and reduces recurrent thrombotic events in stable patients with a previous myocardial infarction (MI). We wished to determine whether the efficacy and safety of antiplatelet therapy with vorapaxar was modified by concurrent thienopyridine use.
P atients with a history of myocardial infarction (MI) are at risk of recurrent thrombotic events. Antiplatelet therapy with aspirin reduces the risk of major cardiovascular events in patients with established atherosclerosis. 1 The addition of more potent antiplatelet therapy to aspirin via P2Y 12 adenosine diphosphate receptor inhibition resulted in a reduction in recurrent cardiovascular events when used for at least 1 year following an acute coronary syndrome or for at least 30 months following percutaneous coronary intervention with drug-eluting stents. [2] [3] [4] [5] [6] [7] However, the benefit of additional antiplatelet therapy beyond aspirin in stable atherosclerosis has been less well established with mixed results. [8] [9] [10] 1872 Circulation
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We have reported in the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic EventsThrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50) trial (NCT00526474) that long-term platelet inhibition with vorapaxar, a potent and selective antagonist of the protease-activated receptor 1 , reduced the rates of cardiovascular death, MI, and stroke in stable patients with established cardiovascular disease. 11 This reduction in ischemic events was associated with an increased risk of serious bleeding, in particular, in patients with a history of stroke. Among patients enrolled in the trial with a history of MI, vorapaxar demonstrated a favorable balance of antithrombotic efficacy and safety. 12 Vorapaxar has since been approved for clinical use in the United States in patients with a history of MI or peripheral arterial disease without a history of stroke or transient ischemic attack. Given the prevalent use of thienopyridines in addition to aspirin in the post-MI population, it is important to understand the potential benefits and risks of adding vorapaxar to a thienopyridine as a second or third antiplatelet agent post-MI. We therefore evaluated the efficacy, safety, and net clinical outcomes with vorapaxar in comparison with placebo in stable patients with a history of MI without previous stroke or transient ischemic attack treated with aspirin alone or aspirin and a thienopyridine.
Methods

Study Population and Procedures
The TRA 2°P-TIMI 50 trial was a multinational, double-blind, randomized, placebo-controlled trial of vorapaxar among 26 449 patients with a history of atherothrombosis. 13 The majority of patients (n=17 779, 67%) were enrolled on the basis of a history of MI (within the previous 2 weeks to 12 months). Patients were ineligible if they had yet to undergo a planned revascularization procedure, had a history of a bleeding disorder or recent abnormal bleeding (within 30 days), or required treatment with an oral anticoagulant. 13 Patients were randomly assigned (1:1) to vorapaxar sulfate 2.5 mg (vorapaxar 2.08 mg) or placebo orally daily. To achieve a balance of baseline characteristics between randomized treatment groups, subject randomization was stratified according to qualifying atherosclerosis (MI, stroke, or peripheral arterial disease), and the treating physician's intention to administer a thienopyridine at the time of randomization, as well. All concomitant medications, including aspirin or thienopyridines, were managed by the patient's physician. The use of a third-generation adenosine diphosphate antagonist (prasugrel and ticagrelor) was permitted where used in standard practice. Treatment with aspirin ≤162 mg was recommended. The ethics committee at each participating center approved the protocol. Written informed consent was obtained from all patients.
End Points
All elements of the composite efficacy and bleeding end points were adjudicated by a clinical events committee blinded to the treatment allocation. The prespecified TIMI statistical analysis plan defined the primary efficacy end point of cardiovascular death, MI, or stroke and principal secondary end points of cardiovascular death, MI, stroke, or urgent coronary revascularization and cardiovascular death or MI. Additional end points assessed included individual components of the above end points. MI was defined by ischemic symptoms and electrocardiographic, biomarker, or pathological evidence of infarction as previously reported in detail. 13 Urgent coronary revascularization was defined as ischemic symptoms that led to an unplanned admission and revascularization. Bleeding events were classified according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) and TIMI systems. The principal safety end point was GUSTO moderate or severe bleeding. End points to assess net clinical outcome have been defined previously, including the composite of all-cause death, MI, stroke, or GUSTO severe bleeding and the composite of cardiovascular death, MI, stroke, urgent coronary revascularization, and GUSTO severe or moderate bleeding.
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Statistical Analysis
All efficacy analyses were by intention-to-treat using Cox proportional hazards modeling with randomization treatment (vorapaxar versus placebo) and intent to use a thienopyridine as a covariate. Safety analyses included all patients given at least 1 dose of study drug and included events occurring up to 60 days after premature cessation or 30 days after study completion. The subgroup analysis by planned thienopyridine use (as reported at the time of randomization) was prespecified. Additional sensitivity analyses were performed based on (1) the actual use of thienopyridine therapy at baseline and (2) consistent therapy at baseline and 18 months of follow-up. In addition, analyses among patients identified as low risk for bleeding as previously described are reported in the online-only Data Supplement. 6, 12 We assessed for heterogeneity by using Cox proportional hazard modeling including a treatment-by-subgroup interaction term. All reported P values are 2-sided. All presented event rates are 3-year Kaplan-Meier estimates. All analyses were conducted using Stata/IC, version 13.1 (StataCorp LP).
Results
Patient Population
Of the 26 449 patients randomly assigned in the TRA 2°P-TIMI 50 study, 16 897 (64%) were enrolled on the basis of a previous MI and did not have a history of stroke or transient ischemic attack. At the time of randomization, 12 410 (73%) subjects in this cohort were planned to receive a thienopyridine. The median follow-up in the analytic cohort was 30 (first quartile, third quartile: 24, 36) months.
The baseline characteristics were well-balanced between vorapaxar-and placebo-treated patients within each thienopyridine treatment stratum (Table 1) . In contrast, patients selected by their providers for treatment with a thienopyridine differed significantly from those not planned to receive a thienopyridine (Table 1) . Patients who had thienopyridine therapy planned were younger with lower rates of diabetes mellitus, hypertension, and renal insufficiency. Patients in the planned thienopyridine cohort also had higher rates of previous coronary revascularization (89.7% versus 76.1%, P<0.0001). Specifically, in the planned thienopyridine stratum, 87.4% had a history of percutaneous coronary intervention and 8.3% had undergone coronary artery bypass grafting, in comparison with 57.5% and 25.7%, respectively, in the no planned thienopyridine stratum (Table 1 and Figure I in the online-only Data Supplement). Patients without planned thienopyridine use at the time of enrollment had a longer median time from their qualifying MI to randomization than those with planned thienopyridine use (5 [2, 9] Table 2 ).
Efficacy of Vorapaxar in the Setting of Thienopyridine Use
The antithrombotic benefit of vorapaxar in comparison with placebo was consistent irrespective of planned thienopyridine therapy. Vorapaxar reduced the risk of cardiovascular death/ MI/stroke by 20% over placebo in the thienopyridine stratum (7.3% versus 9.0%, hazard ratio [HR], 0.80; 95% confidence Sensitivity analyses based on actual thienopyridine use at baseline yielded similar results, where the benefit of vorapaxar over placebo was not altered by thienopyridine use. In those with documented use of a thienopyridine at randomization, rates of cardiovascular death/MI/stroke at 3 years were 7.3% with vorapaxar treatment versus 9.0% in the placebo group (HR, 0.79; 95% CI, 0.69-0.90, P<0.001) in comparison with 7.6% versus 9.1%, respectively, for those not on a thienopyridine at baseline (HR, 0.76; 95% CI, 0.60-0.97, P=0.030, P-interaction = 0.82). In an analysis focused on patients with prolonged use of a thienopyridine (≥18 months, N=7017), vorapaxar similarly lowered the hazard of cardiovascular death, MI, or stroke by 18% in comparison with placebo (11.0% versus 13.2%, HR, 0.82; 95% CI, 0.71-0.95,
P=0.008).
The presence and magnitude of benefit with vorapaxar were consistent across secondary end points and were not altered with or without planned thienopyridine use ( Figure 2 ). The risk of cardiovascular death/MI/stroke/ urgent coronary revascularization was reduced by 18% with vorapaxar in comparison with placebo in patients in the planned thienopyridine group (HR, 0.82; 95% CI, 0.73-0.92, P<0.001) and 19% in the no planned thienopyridine group (HR, 0.81; 95% CI, 0.66-0.98, P=0.034; P-interaction=0.88). Significant reductions were also seen with vorapaxar without interaction by planned thienopyridine use for MI and ischemic stroke (Figure 2 ). There was no increase in all-cause death with vorapaxar in comparison with placebo in either thienopyridine strata (planned thienopyridine, HR, 1.02; 95% CI, 0.82-1.27, P=0.853; no planned thienopyridine, HR, 0.73; 95% CI, 0.54-0.99, P=0.045; P-interaction 0.080).
Safety of Vorapaxar in the Setting of Thienopyridine Use
The absolute rate of GUSTO severe or moderate bleeding was 3.3% in the vorapaxar group in comparison with 2.3% for placebo at 3 years in those with planned thienopyridine use with early separation of the Kaplan-Meier curves and 2.8% versus 1.3%, respectively, in those without planned thienopyridine use where the difference becomes apparent at ≈1 year ( Figure 3A and 3B) . Consistent with the findings in the overall cohort, these rates reveal an increased relative risk of GUSTO moderate to severe bleeding in patients treated with vorapaxar in comparison with placebo; however, there was no significant modification by planned thienopyridine use (planned thienopyridine HR, 1.50; 95% CI, 1.18-1.89, P<0.001; no planned thienopyridine HR, 1.90; 95% CI, 1.17-3.07, P=0.009; P-interaction=0.37, Figure 3A and 3B, Table  3 ). Findings were similar in an exploratory landmark analysis at 12 months (Table I in the online-only Data Supplement). The relative risk of intracranial hemorrhage and fatal bleeding with vorapaxar versus placebo did not differ significantly between thienopyridine groups (Table 3) . Three-year rates of fatal bleeding were 0.2% versus 0.1% in patients receiving vorapaxar versus placebo on top of a thienopyridine (P=0.42). Intracranial hemorrhage rates were 0.5% versus 0.4% in that cohort (P=0.27). Notably, there was a possible interaction (P-interaction=0.017) between vorapaxar and the use of concomitant thienopyridine with respect to the risk of TIMI clinically significant bleeding, which includes TIMI major, minor, and bleeding requiring medical attention ( Figure 3C and 3D, Table 3 ); with the interaction driven by bleeding requiring medical attention (P-interaction=0.012).
Sensitivity analyses in patients with actual thienopyridine use at randomization showed a similar pattern. The relative risk of GUSTO moderate to severe bleeding with vorapaxar was not altered with actual thienopyridine use at baseline (P-interaction=0.24). However, the risk of TIMI clinically 
Net Clinical Outcomes of Vorapaxar in the Setting of Thienopyridine Use
Vorapaxar conferred a significant benefit for the balance of antithrombotic and bleeding events irrespective of thienopyridine use (P-interaction=0.35, 
012).
Net clinical outcomes were similarly improved in a subset of patients previously identified as low risk for bleeding as defined by an age <75 years and weight ≥60 kg (Table II in the online-only Data Supplement). Safety outcomes are described for the remaining subset of patients with at least 1 high-risk feature (Table III in the online-only Data Supplement).
Discussion
Platelet inhibition via protease-activated receptor 1 antagonism with vorapaxar significantly reduces recurrent atherothrombotic events in stable patients with a history of MI with a significant increase in moderate or severe bleeding. 12 We have now investigated the efficacy and safety profile of vorapaxar when administered with aspirin with or without a concurrent thienopyridine, predominantly clopidogrel. We found that vorapaxar decreased the incidence of major cardiovascular events, irrespective of thienopyridine therapy. The increased risk of GUSTO moderate to severe bleeding with vorapaxar was also not modified by thienopyridine use. Although the rates of intracranial hemorrhage and fatal bleeding were very low and not significantly different between vorapaxar-and placebo-treated patients in this analysis, other bleeding events requiring medical attention were increased to a potentially greater magnitude when vorapaxar was administered in the setting of background therapy with a thienopyridine. These findings indicate that vorapaxar is effective for secondary prevention when added to dual-antiplatelet therapy with aspirin and a thienopyridine. At the same time, these results highlight the importance of patient selection with attention to absolute bleeding risk when considering combination potent antiplatelet therapy. Although current guidelines recommend treatment with aspirin and P2Y 12 inhibition for up to 12 months in patients with acute coronary syndrome and for at least 6 to 12 months in patients receiving a drug-eluting stent, the optimal duration of thienopyridine therapy has been uncertain and the subject of recent investigation. [14] [15] [16] [17] [18] [19] [20] [21] Vorapaxar has been demonstrated to reduce major cardiovascular events, both early (<3 months) and late (>12 months) following MI. 12 Because vorapaxar has been approved in the United States for use in patients with previous MI without a history of transient ischemic attack or stroke, there is the possibility of overlapping therapy with vorapaxar, aspirin, and thienopyridine in the post-MI period.
Importantly, we have now shown that the reduction in recurrent thrombotic events with vorapaxar is highly consistent in post-MI patients whether managed with or without a thienopyridine, which was almost entirely clopidogrel in our study. Although bleeding is increased with vorapaxar, the relative risk of moderate or severe bleeding events was not altered by overlap with a thienopyridine, and net clinical outcome was improved with vorapaxar in patients who were also treated with clopidogrel. These findings indicate that in patients with a previous MI, secondary prevention with vorapaxar may be beneficial when initiated early after stabilization from MI in conjunction with ongoing dual-antiplatelet therapy with aspirin and clopidogrel. The antithrombotic benefits of such combination therapy should be weighed against the risk of bleeding. Our findings come in the context of 2 recent trials of P2Y 12 inhibition in patients with ischemic heart disease. The Dual Antiplatelet Therapy (DAPT) study demonstrated a reduction in major cardiovascular events with continued thienopyridine therapy for at least 30 months in comparison with 12 months following drug-eluting stent placement, where MI was the indication for percutaneous coronary intervention in ≈25% of subjects. 5 Additionally, in the PEGASUS-TIMI 54 Trial, extended P2Y 12 inhibition with the addition of ticagrelor to aspirin reduced major cardiovascular events in patients with an MI within 1 to 3 years of enrollment. 10 In both of these trials, the atherothrombotic benefits came at the cost of increased bleeding. Together, these data with vorapaxar, ticagrelor, prasugrel, and clopidogrel yield consistent support for a benefit of extended antiplatelet therapy beyond aspirin alone in patients with stable ischemic heart disease. Moreover, the present analysis from TRA 2°P-TIMI 50 shows a complementary reduction in thrombotic events with concurrent inhibition of the protease-activated receptor 1 and P2Y 12 pathways. Because clopidogrel was the thienopyridine used in the vast majority of patients in the trial as a result of the standard practice patterns during trial conduct, it is not possible to comment on the long-term benefit or risks of vorapaxar in combination with third generation thienopyridines or other P2Y 12 inhibitors.
There are additional limitations to this analysis. Because thienopyridine treatment was not randomized, it is not possible to formally compare outcomes in patients with use versus nonuse of a thienopyridine given the imbalances in patient characteristics between the strata. However, the comparison between vorapaxar and placebo within the thienopyridine strata was randomized, and balance of the treatment groups was achieved through stratification by intention to administer a thienopyridine at randomization, a prerandomization variable. The duration of actual thienopyridine use was determined by the practitioner and varied. However, sensitivity analyses conducted to address these limitations with stratification by actual thienopyridine use at randomization and consistent thienopyridine use for 18 months showed similar results. The median duration of thienopyridine use following randomization was slightly (5%) but significantly (P=0.01) shorter in the vorapaxar arm than in placebo. This may have been attributable to higher discontinuation in the vorapaxar arm secondary to bleeding, less discontinuation in the placebo arm because of increased rates of recurrent atherothrombotic events, or the play of chance. The consistent pattern of efficacy and safety among patients with and without intended thienopyridine use and consistent thienopyridine use for ≥18 months suggests that this finding did not meaningfully impact the results.
Conclusions
These findings demonstrate the efficacy of vorapaxar when added to aspirin and a thienopyridine for secondary prevention in patients with a previous MI. The higher relative risk of moderate or severe bleeding with vorapaxar was not increased by concurrent use of thienopyridine therapy. However, absolute bleeding risk should be considered when selecting patients for combination potent antiplatelet therapy.
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